Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 8/20 | 0.52 |
| ▸ | FEN1 | P39748 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 5/20 | 0.46 |
| ▸ | ATR | Q13535 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 4/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558136 | 0.83 | FEN1 (0.51) | ALOX5APFEN1PRKDCATRATM | |
| SCHEMBL30829217 | 0.83 | FEN1 (0.51) | ALOX5APFEN1PRKDCATRATM | |
| SCHEMBL387688 | 0.79 | ENPP2 (0.47) | KCNH2PTGS2PRKDCATRATM | |
| SCHEMBL4488979 | 0.79 | MAP4K4 (0.54) | KCNH2FYNMAP4K4MINK1TNIK | |
| SCHEMBL15918540 | 0.79 | ALOX5AP (0.74) | ALOX5APFEN1 | |
| SCHEMBL11371855 | 0.76 | NOS3 (0.50) | ALOX5APFEN1 | |
| SCHEMBL15308507 | 0.76 | KCNH2 (0.60) | KCNH2PRKDCATRATM | |
| SCHEMBL387593 | 0.75 | ALOX5AP (0.64) | ALOX5APFEN1 | |
| SCHEMBL28101536 | 0.75 | ATR (0.47) | ALOX5APFEN1PRKDCATRATM | |
| SCHEMBL30139279 | 0.75 | ATR (0.44) | ALOX5APFEN1PRKDCATRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518856-A | Pyrazine derivatives useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-106496209-A | It is used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496210-A | It is used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| EP-2814820-B1 | ANTI-MALARIAL AGENTS | UNIV CAPE TOWN (ZA) | 2016-07-20 | — | — | EP | disclosed |
| EP-2814820-B1 | ANTI-MALARIAL AGENTS | UNIV CAPE TOWN (ZA) | 2016-07-20 | — | — | EP | disclosed |
| CN-102731492-B | Cyclohexanes derivant, its preparation method and in application pharmaceutically | 江苏恒瑞医药股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9062008-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-23 | — | — | US | disclosed |
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2011143423-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143423-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ALOX5AP 3656/4885FEN1 733/4885KCNH2 2655/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | ALOX5AP 2945/4885FEN1 3869/4885KCNH2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.